ABBV-154
Conditions
Keywords
ABBV-154
Brief summary
This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.
Interventions
DRUGABBV-154 Dose Formulation A
Subcutaneous Injection
DRUGABBV-154 Dose Formulation B
Subcutaneous Injection
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
\- Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the nearest tenth at screening and upon initial confinement.
Exclusion criteria
* Participant using any medications, vitamins and/or herbal supplements, within the 2 week period or 5 half-lives (whichever is longer) prior to study drug administration. * History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease, glaucoma, psychiatric disease or disorder, or any uncontrolled medical illness. * Prior exposure to similar biologic therapies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | Approximately up to 58 days | Maximum Observed Plasma Concentration (Cmax) |
| Time to Maximum Observed Plasma Concentration (Tmax) | Approximately up to 58 days | Time to Maximum Observed Plasma Concentration (Tmax) |
| Apparent Terminal Phase Elimination Rate Constant (β) | Approximately up to 58 days | Apparent Terminal Phase Elimination Rate Constant (β) |
| The Terminal Phase Elimination Half-Life (t1/2) | Approximately up to 58 days | The Terminal Phase Elimination Half-Life (t1/2) |
| The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) | Approximately up to 58 days | The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) |
| The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞) | Approximately up to 58 days | The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞) |
| Number of Participants with Adverse Events | Approximately up to 72 days | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
Countries
United States
Outcome results
None listed